# A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

> **NCT06632860** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Iodine-resistant Thyroid Cancer
- Meningioma
- NETs

## Interventions

- **DRUG:** 68Ga-TATE-RGD
- **DRUG:** 18-FDG

## Key facts

- **NCT ID:** NCT06632860
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-12-20
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632860, "A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06632860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*